Mathilde Boussac1, Christophe Arbus2, Julia Dupouy3, Estelle Harroch4, Vanessa Rousseau4, Aurélie Croiset5, Fabienne Ory-Magne1,4, Olivier Rascol1,4, Caroline Moreau6, Anne-Sophie Rolland6, David Maltête7,8, Tiphaine Rouaud9, Mylène Meyer10, Sophie Drapier11,12, Bruno Giordana13, Mathieu Anheim14,15,16, Elodie Hainque17, Béchir Jarraya18,19, Isabelle Benatru20, Nicolas Auzou21, Lhaouas Belamri22, Mélissa Tir23, Ana-Raquel Marques24, Stephane Thobois25,26,27, Alexandre Eusebio28, Jean Christophe Corvol17, David Devos6, Christine Brefel-Courbon1,4. 1. Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France. 2. Psychiatry Department of the University Hospital of Toulouse, CHU Purpan, Toulouse, France. 3. Department of Neurology, Hospital of Avignon, Avignon, France. 4. Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Center, NS-PARK/FCRIN Network, Toulouse, France. 5. CERPPS-Study and Research Center in Psychopathology and Health Psychology, University of Toulouse II Jean-Jaurès, Toulouse, France. 6. Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, NS-PARK/FCRIN Network, Lille, France. 7. Department of Neurology, Rouen University Hospital and University of Rouen, Rouen, France. 8. Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, INSERM U1239, NS-PARK/FCRIN Network, Mont-Saint-Aignan, France. 9. Clinique Neurologique, Hôpital Guillaume et René Laennec, NS-PARK/FCRIN Network, Boulevard Jacques Monod, Nantes, France. 10. Neurology Department, Nancy University Hospital, Nancy, France. 11. Behavior and Basal Ganglia Research Unit (EA 4712), University of Rennes 1, Rennes, France. 12. Department of Neurology, Rennes University Hospital, NS-PARK/FCRIN Network, Rennes, France. 13. Service Universitaire de Psychiatrie, Hôpital Pasteur 1, CHU de Nice, Nice, France. 14. Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. 15. Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France. 16. Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, NS-PARK/FCRIN Network, Strasbourg, France. 17. Département de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, and CNRS UMR 7225, and Institut du Cerveau et de la Moëlle épinière, NS-PARK/FCRIN Network, Paris, France. 18. Pôle Neurosciences, Foch Hospital, Suresnes, France. 19. Université de Versailles Paris-Saclay, INSERM U992, CEA Neurospin, France. 20. Service de Neurologie, Centre Expert Parkinson, CIC-INSERM 1402, CHU Poitiers, NS-PARK/FCRIN Network, Poitiers, France. 21. CHU de Bordeaux, Centre Expert Parkinson, Institut des maladies neuro-dégénératives, Bordeaux, France. 22. Hôpital Fondation A de Rothschild, Service de recherche clinique, Paris, France. 23. Department of Neurology, Department of Neurosurgery, Expert Centre for Parkinson's disease, Amiens University Hospital, EA 4559 Laboratoire de Neurosciences Fonctionnelles et Pathologie (LNFP) Université de Picardie Jules Verne, University of Picardy Jules Verne (UPJV), NS-PARK/FCRIN Network, Amiens, France. 24. Neurology Department, Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, NS-PARK/FCRIN Network, Clermont-Ferrand, France. 25. Univ Lyon, Université Claude Bernard Lyon 1, Faculté de Médecine Lyon Sud Charles Mérieux, Lyon, France. 26. CNRS, Institut des Sciences Cognitives, UMR 5229, Bron, France. 27. Centre Expert Parkinson, Hôpital Neurologique "Pierre Wertheimer", Hospices Civils de Lyon, NS-PARK/FCRIN Network, Lyon, France. 28. Aix Marseille Université, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement, and UMR CNRS 7289, Institut de Neuroscience de La Timone, NS-PARK/FCRIN Network, Marseille, France.
Abstract
BACKGROUND: Studies assessing personality dimensions by the "Temperament and Character Inventory" (TCI) have previously found an association between Parkinson's disease (PD) and lower Novelty Seeking and higher Harm Avoidance scores. Here, we aimed to describe personality dimensions of PD patients with motor fluctuations and compare them to a normative population and other PD populations. METHODS: All PD patients awaiting Deep Brain Stimulation (DBS) answered the TCI before neurosurgery. Their results were compared to those of historical cohorts (a French normative population, a de novo PD population, and a PD population with motor fluctuations). RESULTS: Most personality dimensions of our 333 included PD patients with motor fluctuations who are candidates for DBS were different from those of the normative population and some were also different from those of the De Novo PD population, whereas they were similar to those of another population of PD patients with motor fluctuations. CONCLUSIONS: During the course of PD, personality dimensions can change in parallel with the development of motor fluctuations, either due to the evolution of the disease and/or dopaminergic treatments.
BACKGROUND: Studies assessing personality dimensions by the "Temperament and Character Inventory" (TCI) have previously found an association between Parkinson's disease (PD) and lower Novelty Seeking and higher Harm Avoidance scores. Here, we aimed to describe personality dimensions of PDpatients with motor fluctuations and compare them to a normative population and other PD populations. METHODS: All PDpatients awaiting Deep Brain Stimulation (DBS) answered the TCI before neurosurgery. Their results were compared to those of historical cohorts (a French normative population, a de novo PD population, and a PD population with motor fluctuations). RESULTS: Most personality dimensions of our 333 included PDpatients with motor fluctuations who are candidates for DBS were different from those of the normative population and some were also different from those of the De Novo PD population, whereas they were similar to those of another population of PDpatients with motor fluctuations. CONCLUSIONS: During the course of PD, personality dimensions can change in parallel with the development of motor fluctuations, either due to the evolution of the disease and/or dopaminergic treatments.
Authors: V Kaasinen; E Nurmi; J Bergman; O Eskola; O Solin; P Sonninen; J O Rinne Journal: Proc Natl Acad Sci U S A Date: 2001-10-30 Impact factor: 11.205
Authors: Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak Journal: Neurobiol Aging Date: 2003 Mar-Apr Impact factor: 4.673